Loading…
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $292M | $42M | $1M | $28M | 4.0% | 43.7% | -101.0% |
| 2024 | $203M | $-14M | $-55M | $-38M | 185.2% | 23.9% | -11.9% |
| 2023 | $164M | $-24M | $-62M | $-49M | 917.9% | 48.7% | -34.2% |
| 2022 | $110M | $-69M | $-95M | $-103M | -209.5% | - | - |
| 2021 |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 110.25 | 163.91 | 203.07 | 291.85 |
| Operating Revenue | - | 110.25 | 163.91 | 203.07 | 291.85 |
| Cost Of Revenue | - | 22.63 | 28.64 | 36.83 | 42.57 |
| Gross Profit | - | 87.61 | 135.27 | 166.24 | 249.28 |
| Operating Expense | - | 169.55 | 179.28 | 199.88 | 224.38 |
| Research And Development | - | 20.97 | 22.34 | 25.56 | 31.16 |
| Selling General And Administration | - | 137.74 | 146.10 | 163.48 | 182.37 |
| Total Expenses | - | 192.19 | 207.92 | 236.72 | 266.95 |
| Operating Income | - | -81.94 | -44.01 | -33.65 | 24.90 |
| Total Operating Income As Reported | - | -81.94 | -44.01 | -33.65 | 24.90 |
| EBITDA | - | -69.31 | -23.74 | -13.99 | 42.33 |
| Normalized EBITDA | - | -66.69 | -26.10 | -15.70 | 42.33 |
| EBIT | - | -81.98 | -36.90 | -26.62 | 29.64 |
| Interest Income | - | 2.58 | 4.75 | 5.32 | 4.74 |
| Interest Expense | - | 14.10 | 26.61 | 30.48 | 29.08 |
| Net Interest Income | - | -11.52 | -21.86 | -25.16 | -24.34 |
| Other Income Expense | -0.70 | -2.62 | 2.36 | 1.71 | - |
| Interest Income Non Operating | - | 2.58 | 4.75 | 5.32 | 4.74 |
| Interest Expense Non Operating | - | 14.10 | 26.61 | 30.48 | 29.08 |
| Net Non Operating Interest Income Expense | - | -11.52 | -21.86 | -25.16 | -24.34 |
| Pretax Income | - | -96.08 | -63.50 | -57.10 | 0.55 |
| Tax Provision | - | -1.42 | -1.25 | -2.27 | 0 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -0.04 | 0.05 | 0.07 | 0 |
| Net Income Continuous Operations | - | -94.66 | -62.26 | -54.84 | 0.55 |
| Net Income From Continuing And Discontinued Operation | - | -94.66 | -62.26 | -54.84 | 0.55 |
| Net Income From Continuing Operation Net Minority Interest | - | -94.66 | -62.26 | -54.84 | 0.55 |
| Net Income | - | -94.66 | -62.26 | -54.84 | 0.55 |
| Net Income Common Stockholders | - | -94.66 | -62.26 | -54.84 | 0.55 |
| Net Income Including Noncontrolling Interests | - | -94.66 | -62.26 | -54.84 | 0.55 |
| Normalized Income | - | -92.08 | -64.57 | -56.47 | 0.55 |
| Diluted NI Availto Com Stockholders | - | -94.66 | -62.26 | -54.84 | 0.55 |
| Basic Average Shares | - | 135.63 | 137.67 | 146.77 | 160.43 |
| Diluted Average Shares | - | 135.63 | 137.67 | 146.77 | 172.74 |
| Reconciled Depreciation | - | 12.67 | 13.16 | 12.62 | 12.69 |
| Reconciled Cost Of Revenue | - | 20.81 | 26.33 | 35.05 | 40.72 |
| Total Unusual Items | - | -2.62 | 2.36 | 1.71 | 0 |
| Total Unusual Items Excluding Goodwill | - | -2.62 | 2.36 | 1.71 | 0 |
| Special Income Charges | - | -4.38 | 2.36 | 1.70 | 0 |
| Other Special Charges | - | 1.22 | 2.84 | 2.69 | - |
| Restructuring And Mergern Acquisition | - | 3.16 | -5.20 | -4.39 | 0 |
| Gain On Sale Of Security | -0.70 | 1.76 | 0 | 0.01 | - |
| Depreciation Amortization Depletion Income Statement | - | 10.84 | 10.84 | 10.84 | 10.84 |
| Depreciation And Amortization In Income Statement | - | 10.84 | 10.84 | 10.84 | 10.84 |
| Total Other Finance Cost | - | - | - | 2.69 | - |
| Amortization | - | 10.84 | 10.84 | 10.84 | 10.84 |
| Amortization Of Intangibles Income Statement | - | 10.84 | 10.84 | 10.84 | 10.84 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings, Inc.this co. | XERS | $1.1B | 1916.51↑ premium | 77.56 | 4.0% | 28.56 |
| MannKind Corporation | MNKD | $1.1B | 185.49 | -21.31 | -11.5% | 26.79 |
| Savara Inc. | SVRA | $1.1B | -9.14 | 5.35 | -58.5% | -8.83 |
| Omada Health, Inc. | OMDA | $1.1B | -84.72 | 4.71 | -5.6% | -181.05 |
| Collegium Pharmaceutical, Inc. | COLL |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $1.1B |
| 16.86 |
| 3.51 |
| 20.8% |
| 4.10 |
| CONMED Corporation | CNMD | $1.1B | 22.48 | 1.02 | 4.6% | 10.49 |
| Azenta, Inc. | AZTA | $1.1B | -18.88 | 0.61 | -3.2% | 20.85 |
| The Pennant Group, Inc. | PNTG | $1.0B | 35.40 | 3.15 | 8.9% | 24.38 |
| QuidelOrtho Corporation | QDEL | $1.0B | -0.92 | 0.54 | -58.9% | -7.68 |
| Peer Median | - | 7.97 | 2.09 | -4.4% | 7.30 | |